Who is sponsoring NCT04830462?

NCT04830462 is sponsored by Herlev and Gentofte Hospital.

What drugs are being tested in NCT04830462?

Interventions in NCT04830462: Rifampicin 300 Mg Oral Capsule, Isoniazid 300 Mg ORAL TABLET.

What condition does NCT04830462 study?

NCT04830462 studies Latent Tuberculosis, Diabetes Mellitus, Type 2.

Is NCT04830462 still recruiting?

NCT04830462 is currently completed. Last updated 16 May 2023.

Last reviewed 2023-05-16 · How we verify

NCT04830462

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation

Completed Phase 4 Last updated 16 May 2023

What this trial tests

Phase 4 trial testing Rifampicin 300 Mg Oral Capsule in Latent Tuberculosis in 32 participants. Completed in 1 May 2023.

Timeline

15 April 2021

Primary endpoint
1 May 2023

1 May 2023

Quick facts

Lead sponsor	Herlev and Gentofte Hospital
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	basic science
Enrollment	32
Start date	15 April 2021
Primary completion	1 May 2023
Estimated completion	1 May 2023
Sites	1 location across Denmark

Drugs / interventions tested

Rifampicin 300 Mg Oral Capsule — full drug profile →
Isoniazid 300 Mg ORAL TABLET

Conditions studied

Latent Tuberculosis — all drugs for Latent Tuberculosis →
Diabetes Mellitus, Type 2 — all drugs for Diabetes Mellitus, Type 2 →

Sponsor

Herlev and Gentofte Hospital

Who can join

18 and older, any sex, with Latent Tuberculosis or Diabetes Mellitus, Type 2. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will be investigating the effect of latent tuberculosis infection (LTBI) treatment on glucose tolerance and low-grade inflammation. Almost a century ago, researchers proposed that diabetes (DM) was associated with increased risk of Tuberculosis infection (TB). A more recent systematic review concluded that DM increases the relative risk for TB 3.1 times. Reversely, TB may affect the glycaemic control; TB is in many cases a chronic infection characterised by long term low-grade inflammation and weight loss, and persons with TB are known to be at risk of hyperglycaemia and DM at time of diagnosis. A latent infection with the m.tuberculosis bacteria is "silent" without symptoms. 1,7 billion have LTBI on a global scale. Event though the infected person does not experience symptoms, increased background inflammation has been shown in LTBI patients in previous studies. We also know that an increase in inflammatory markers precedes clinical development of DM, and that subclinical inflammation contributes to insulin resistance. We hypothesise that LTBI contributes to dysregulated glucose metabolism due to increased low-grade inflammation, and that treatment will reduce low-grade inflammation and improve glucose tolerance.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

The impact of an oral glucose load on IFN-γ-release in persons infected with Mycobacterium tuberculosis.
Lorentsson HJN, Clausen CR, Faurholt-Jepsen D, Hansen KB, et al · · 2024 · PMID 39350021 · DOI 10.1186/s12879-024-09920-x
The effect of Mycobacterium tuberculosis treatment on thrombelastography-assessed haemostasis: a prospective cohort study.
Lorentsson HJN, Clausen CR, Faurholt-Jepsen D, Hansen KB, et al · · 2024 · PMID 38918780 · DOI 10.1186/s12959-024-00625-4

Verify or expand the search:

Other recruiting trials for Latent Tuberculosis

Currently open trials in the same condition.

NCT06526689 — Lung Innate Immunity and Microbiome After Tuberculosis Exposure · recruiting
NCT06022146 — TB YOUTH - TB sYstemic Management Using One-month, Ultra-short TPT Regimen for scHool Contacts · Phase 3 · recruiting
NCT05411744 — One-month Latent Tuberculosis Treatment for Renal Transplant Candidates · Phase 4 · active not recruiting
NCT05412212 — Brief Educational Video for Patients Prescribed LTBI Treatment · NA · active not recruiting
NCT05022862 — Economic Incentives and vDOT for Latent Tuberculosis Infection · NA · recruiting

Other Herlev and Gentofte Hospital trials

Trials by the same sponsor.

NCT07493590 — CAPTURE-HFpEF: National Study of Identification and Phenotyping of Heart Failure With Preserved Ejection Fraction · not yet recruiting
NCT07321964 — The Effect of a Digital MediYoga Program on Quality of Life, Blood Pressure and Heart Rate Among Patients With Atrial Fi · NA · recruiting
NCT06706661 — Implementation of Nutritional Efforts on Discharged Older Patients · NA · recruiting
NCT06618417 — Evaluating the Impact of Home-Based Sleep Apnea Diagnostic on Well-Being, Health Behavior, and AF Load in Patients with · NA · recruiting
NCT06642272 — A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Hea · Phase 4 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04830462 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Herlev and Gentofte Hospital
Last refreshed: 16 May 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04830462.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing